Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART

Journal of Infection

Volumn 54, Issue 1, 2007, Pages 89-97

  Haugaard, Steen B ^a   Andersen, Ove ^a   Madsbad, Sten ^a   Iversen, Johan ^a   Dela, Flemming ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endogenous glucose production; Glucose oxidation; HIV infection; Hyperinsulinemia; Insulin sensitivity; Lactate; Normoglycemia; Pyruvate

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; INSULIN; LACTIC ACID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG SAFETY; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE OXIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTATE BLOOD LEVEL; METABOLIC RATE; MITOCHONDRIAL DNA DEPLETION; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE OXIDASE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LACTIC ACID; MIDDLE AGED;

EID: 33845575430     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.01.003     Document Type: Article

References (32)

1. Boubaker K., Flepp M., Sudre P., Furrer H., Haensel A., Hirschel B., et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 33 (2001) 1931-1937
2. Moyle G.J., Datta D., Mandalia S., Morlese J., Asboe D., and Gazzard B.G. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16 (2002) 1341-1349
3. Brinkman K., ter Hofstede H.J., Burger D.M., Smeitink J.A., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12 (1998) 1735-1744
4. Dela F., Mikines K.J., von Linstow M., Secher N.H., and Galbo H. Effect of training on insulin-mediated glucose uptake in human muscle. Am J Physiol 263 (1992) E1134-E1143
5. Veech R.L. The metabolism of lactate. NMR Biomed 4 (1991) 53-58
6. Lovejoy J., Newby F.D., Gebhart S.S., and DiGirolamo M. Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulin. Metabolism 41 (1992) 22-27
7. Yki-Jarvinen H., Bogardus C., and Foley J.E. Regulation of plasma lactate concentration in resting human subjects. Metabolism 39 (1990) 859-864
8. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Richelsen B., Nielsen J.O., et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 77 (2005) 29-38
9. Cote H.C., Brumme Z.L., Craib K.J., Alexander C.S., Wynhoven B., Ting L., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346 (2002) 811-820
10. Polo R., Martinez S., Madrigal P., and Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr 34 (2003) 32-36
11. Nolan D., Hammond E., Martin A., Taylor L., Herrmann S., McKinnon E., et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 17 (2003) 1329-1338
12. Walker U.A., Bickel M., Lutke Volksbeck S.I., Ketelsen U.P., Schofer H., Setzer B., et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 29 (2002) 117-121
13. Haugaard S.B., Andersen O., Dela F., Holst J.J., Storgaard H., Fenger M., et al. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 152 (2005) 103-112
14. Dela F., Larsen J.J., Mikines K.J., Ploug T., Petersen L.N., and Galbo H. Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 44 (1995) 1010-1020
15. Chen D., Misra A., and Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87 (2002) 4845-4856
16. Carr A., Emery S., Law M., Puls R., Lundgren J.D., and Powderly W.G. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361 (2003) 726-735
17. Andersen O., Haugaard S.B., Andersen U.B., Friis-Moller N., Storgaard H., Volund A., et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 52 (2003) 1343-1353
18. Frayn K.N. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55 (1983) 628-634
19. Fogh-Andersen N., and D'Orazio P. Proposal for standardizing direct-reading biosensors for blood glucose. Clin Chem 44 (1998) 655-659
20. Haugaard S.B., Andersen O., Hansen B.R., Andersen U.B., Volund A., Iversen J., et al. In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. Metabolism 54 (2005) 171-179
21. Holten M.K., Zacho M., Gaster M., Juel C., Wojtaszewski J.F., and Dela F. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 53 (2004) 294-305
22. Edgerton D.S., Cardin S., Pan C., Neal D., Farmer B., Converse M., et al. Effects of insulin deficiency or excess on hepatic gluconeogenic flux during glycogenolytic inhibition in the conscious dog. Diabetes 51 (2002) 3151-3162
23. Itoh S., Yougel T., and Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 82 (1987) 650-654
24. Bauer A.M., Sternfeld T., Horster S., Schunk M., Goebel F.D., and Bogner J.R. Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Med 5 (2004) 371-376
25. Lonergan J.T., McComsey G.A., Fisher R.L., Shalit P., File T.M., Ward D.J., et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 36 (2004) 935-942
26. Rossignol R., Malgat M., Mazat J.P., and Letellier T. Threshold effect and tissue specificity. Implication for mitochondrial cytopathies. J Biol Chem 274 (1999) 33426-33432
27. Stacpoole P.W. Lactic acidosis and other mitochondrial disorders. Metabolism 46 (1997) 306-321
28. Murata H., Hruz P.W., and Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275 (2000) 20251-20254
29. Ben Romano R., Rudich A., Tirosh A., Potashnik R., Sasaoka T., Riesenberg K., et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 47 (2004) 1107-1117
30. Cammalleri C., and Germinario R.J. The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. J Lipid Res 44 (2003) 103-108
31. Noor M.A., Seneviratne T., Aweeka F.T., Lo J.C., Schwarz J.M., Mulligan K., et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16 (2002) F1-F8
32. Sutinen J., Hakkinen A.M., Westerbacka J., Seppala-Lindroos A., Vehkavaara S., Halavaara J., et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16 (2002) 2183-2193